Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·CAR-T treatment must target cancer and limit harm
Review or Meta-AnalysisA 2021 review considers CAR-T therapy in blood cancers and solid tumors, and proposes combined approaches to improve tumor control while limiting adverse effects.
-
Evidence date ·What did a 2021 review find about liver cancer treatment?
Review or Meta-AnalysisA review examined 23 published liver cancer trials and two trial abstracts. Few drugs tested after sorafenib proved effective, while immunotherapy was emerging.
-
Evidence date ·Why has an immune-cell activation signal been hard to turn into cancer treatment?
Review or Meta-AnalysisTracked over timeA 2026 review explains why the T cell carrying OX40 matters and why limited responses to drugs used alone are driving research into combinations.
-
Evidence date ·What does an OX40 immune boost need around it to help fight a tumor?
Review or Meta-AnalysisTracked over timeEarly OX40 combinations added little to checkpoint treatment in patients. A 2023 review examines timing, tumor recognition and drug design as possible reasons.
-
Evidence date ·What a patent review shows about OX40 cancer drug development
Review or Meta-AnalysisTracked over timeThe review reports rising OX40 agonist patent activity, especially in 2018 and 2019, and says six candidates represented 68% of related trials.
-
Evidence date ·How daily function related to response and serious harms during lung cancer immunotherapy
Review or Meta-AnalysisTracked over timeA 67-study analysis found lower response and shorter survival among treated patients with limited daily function, but no clear difference in severe side effects.
-
Evidence date ·A striking return of function in three people with advanced lung cancer
Review or Meta-AnalysisTracked over timeThree people with advanced lung cancer had a striking improvement in daily function after immunotherapy. The case series cannot show how often it happens or why.
-
Evidence date ·How cancer treatment can enlist a person’s immune cells
Review or Meta-AnalysisA 2021 review describes two cancer immunotherapy strategies: using antibodies to inhibit proteins on cancer cells and engineering or boosting a person's T cells.
-
Evidence date ·Why did blocking immune escape draw attention in triple-negative breast cancer?
Review or Meta-AnalysisEarly trials reported tumor responses or disease control in treatment-resistant metastatic breast cancer, especially triple-negative disease; lasting patient benefit remained uncertain.
-
Evidence date ·After lymphoma returned, pembrolizumab brought a second scan response
Review or Meta-AnalysisAfter engineered T-cell therapy, one man's lymphoma returned. Scans showed no active lymphoma during pembrolizumab, but lung inflammation cut treatment short.